Midazolam Mercury Pharmaceuticals (Midazolam)

Midazolam enhances the activity of the GABA‑A receptor by binding to its benzodiazepine site, which increases the inhibitory effect of GABA on neuronal firing. This results in sedation, anxiolysis, amnesia, and muscle relaxation.

The dose of Midazolam is individualized and determined by the prescribing clinician based on the patient’s age, weight, clinical condition, and the intended procedure. No fixed dosing regimen is provided here.

Safety data for Midazolam in pregnancy and lactation are limited. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and clinicians should follow local guidelines and consider alternative therapies when possible.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Midazolam offers rapid onset, short duration, and a predictable recovery profile compared with longer‑acting benzodiazepines such as diazepam. Compared with propofol, it provides less profound hypnosis but has a favorable safety margin for brief procedures and is easier to reverse with flumazenil.

Midazolam injectable solution should be stored at ambient temperature, below 25 °C, in its original packaging. Protect it from moisture, direct sunlight, and extreme temperatures. Do not freeze; inspect the vial for particulate matter before use.

Midazolam is administered by intramuscular or intravenous injection. The route, rate of injection, and total dose are determined by the prescriber, who monitors the patient’s vital signs throughout the procedure.

The most serious risks include severe respiratory depression, paradoxical agitation, cardiac arrhythmias, and rare anaphylactic reactions. Continuous monitoring of respiratory and cardiovascular status is essential, especially when combined with other depressant drugs.

Midazolam is contraindicated in patients with known hypersensitivity to benzodiazepines, severe respiratory insufficiency, acute narrow‑angle glaucoma, and in individuals who have taken large quantities of other CNS depressants. Caution is also advised for patients with significant hepatic impairment.